HLA-DQ9

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
HLA-DQ9
(MHC Class II, DQ cell surface antigen)
DQ Illustration.PNG
Illustration of HLA-DQ with bound peptide.
Cis-haplotype Haplotype
isoform, subtype DQA1 DQB1
DQ α2β9 DQ9.2 *0201 *0303
DQ α3β9 DQ9.3 *0302 *0303

HLA-DQ9 (DQ9) is a human leukocyte antigen serotype within the HLA-DQ (DQ) serotype group. DQ9 is a split antigen of the DQ3 broad antigen. DQ9 is determined by the antibody recognition of β9 and this generally detects the gene product of DQB1*0303.

Serology

DQ2, DQ3, DQ7, DQ8, and DQ9 recognition of DRB1*0303 product[1]
DQ9 DQ3 DQ2 DQ7 DQ8 sample
% % % % % (N)
*0303 67 12 11 1 1 2563
Red indicates the level of 'false' reaction in non-DQ9 serotypes
Alleles link-out to IMGT/HLA Databease at EBI

The serotyping efficiency of DQ9 is poor. The recognition of DQB1*0303 by DQ9 and or DQ3 is poorest, DQ2 which recognizes a different DQB1 subgroup recognizes DQB1*0303 as efficiently as DQ3. For this reason DQ9 serotyping is a poor method of typing for transplantation or disease association prediction or study.

DQB1*0303

(DQ9) is associated with nasal polyps,[2] gestational diabetes,[3] microscopic polyangiitis (Japanese). Primary linkage is with DRB1*0901-DQB1*0303 [4]

Haplotypes and disease

DQ9.2

DQA1*0201:DQB1*0303 is associated with type I psoriasis (vulgaris),[5][6]

DQ9.3

DQA1*0302:DQB1*0303 maybe associated with juvenile diabetes in the orient.[7][8] (Chinese) Primary linkage of vitiligo is with DQA1*03-DQB1*0303.[9]

References

  1. ^ derived from IMGT/HLA
  2. ^ Zhai L, Sun Y, Tang L, Liu H (2007). "Polymorphism between loci for human leukocyte antigens DR and DQ in patients with nasal polyps". Ann. Otol. Rhinol. Laryngol. 116 (1): 66–8. doi:10.1177/000348940711600111. PMID 17305280.
  3. ^ Törn C, Gupta M, Sanjeevi CB, Aberg A, Frid A, Landin-Olsson M (2004). "Different HLA-DR-DQ and MHC class I chain-related gene A (MICA) genotypes in autoimmune and nonautoimmune gestational diabetes in a Swedish population". Hum. Immunol. 65 (12): 1443–50. doi:10.1016/j.humimm.2004.09.002. PMID 15603871.
  4. ^ Tsuchiya N, Kobayashi S, Hashimoto H, Ozaki S, Tokunaga K (2006). "Association of HLA-DRB1*0901-DQB1*0303 haplotype with microscopic polyangiitis in Japanese". Genes Immun. 7 (1): 81–4. doi:10.1038/sj.gene.6364262. PMID 16208405.
  5. ^ Schmitt-Egenolf M, Boehncke WH, Ständer M, Eiermann TH, Sterry W (1993). "Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype". J. Invest. Dermatol. 100 (6): 749–52. doi:10.1111/1523-1747.ep12476080. PMID 8496614.
  6. ^ Zhang X, Wei S, Yang S, et al. (2004). "HLA-DQA1 and DQB1 alleles are associated with genetic susceptibility to psoriasis vulgaris in Chinese Han". Int. J. Dermatol. 43 (3): 181–7. doi:10.1111/j.1365-4632.2004.02098.x. PMID 15009387.
  7. ^ Maruyama T, Shimada A, Kasuga A, et al. (1994). "Analysis of MHC class II antigens in Japanese IDDM by a novel HLA-typing method, hybridization protection assay". Diabetes Res. Clin. Pract. 23 (2): 77–84. doi:10.1016/0168-8227(94)90014-0. PMID 8070305.
  8. ^ Ikegami H, Kawaguchi Y, Yamato E, et al. (1992). "Analysis by the polymerase chain reaction of histocompatibility leucocyte antigen-DR9-linked susceptibility to insulin-dependent diabetes mellitus". J. Clin. Endocrinol. Metab. 75 (5): 1381–5. doi:10.1210/jc.75.5.1381. PMID 1358911.
  9. ^ Xia Q, Zhou WM, Liang YH, et al. (2006). "MHC haplotypic association in Chinese Han patients with vitiligo". Journal of the European Academy of Dermatology and Venereology : JEADV. 20 (8): 941–6. doi:10.1111/j.1468-3083.2006.01686.x. PMID 16922942.
Retrieved from "https://en.wikipedia.org/w/index.php?title=HLA-DQ9&oldid=869847584"
This content was retrieved from Wikipedia : http://en.wikipedia.org/wiki/HLA-DQ9
This page is based on the copyrighted Wikipedia article "HLA-DQ9"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA